Colleen M. Kusy
Stock Analyst at Robert W. Baird
(0.14)
# 4,255
Out of 4,355 analysts
239
Total ratings
35.5%
Success rate
-7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen M. Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintained: Buy | $12 → $21 | $10.96 | +91.61% | 3 | May 6, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $90 | $73.50 | +22.45% | 8 | Apr 14, 2026 | |
| KPTI Karyopharm Therapeutics | Maintained: Buy | $21 → $15 | $9.10 | +64.84% | 35 | Mar 25, 2026 | |
| IMMP Immutep | Downgraded: Hold | n/a | $0.4389 | - | 1 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $132 | $93.01 | +41.92% | 1 | Mar 9, 2026 | |
| ARGX argenx SE | Maintained: Hold | $858 → $867 | $835.99 | +3.71% | 4 | Feb 27, 2026 | |
| IOVA Iovance Biotherapeutics | Maintained: Hold | $3 → $4 | $4.10 | -2.44% | 44 | Feb 25, 2026 | |
| COGT Cogent Biosciences | Maintained: Hold | $34 → $35 | $34.96 | +0.11% | 11 | Feb 19, 2026 | |
| NUVL Nuvalent | Maintained: Buy | $112 → $158 | $110.39 | +43.13% | 6 | Nov 18, 2025 | |
| OCUL Ocular Therapeutix | Maintained: Buy | $17 → $24 | $9.01 | +166.37% | 19 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $52 | $39.57 | +31.41% | 5 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 → $6 | $3.50 | +71.43% | 14 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.45 | n/a | 28 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $41 | $22.71 | n/a | 14 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $6 | $1.59 | n/a | 13 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $33 | $13.58 | n/a | 15 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $3.60 | n/a | 8 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $3 | $0.0001 | n/a | 7 | Apr 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $31 | $19.59 | n/a | 3 | Jun 3, 2021 |
Climb Bio
May 6, 2026
Maintained: Buy
Price Target: $12 → $21
Current: $10.96
Upside: +91.61%
Spyre Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $90
Current: $73.50
Upside: +22.45%
Karyopharm Therapeutics
Mar 25, 2026
Maintained: Buy
Price Target: $21 → $15
Current: $9.10
Upside: +64.84%
Immutep
Mar 13, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.4389
Upside: -
Dianthus Therapeutics
Mar 9, 2026
Maintained: Buy
Price Target: $132
Current: $93.01
Upside: +41.92%
argenx SE
Feb 27, 2026
Maintained: Hold
Price Target: $858 → $867
Current: $835.99
Upside: +3.71%
Iovance Biotherapeutics
Feb 25, 2026
Maintained: Hold
Price Target: $3 → $4
Current: $4.10
Upside: -2.44%
Cogent Biosciences
Feb 19, 2026
Maintained: Hold
Price Target: $34 → $35
Current: $34.96
Upside: +0.11%
Nuvalent
Nov 18, 2025
Maintained: Buy
Price Target: $112 → $158
Current: $110.39
Upside: +43.13%
Ocular Therapeutix
Oct 3, 2025
Maintained: Buy
Price Target: $17 → $24
Current: $9.01
Upside: +166.37%
Jun 16, 2025
Maintained: Buy
Price Target: $40 → $52
Current: $39.57
Upside: +31.41%
Jun 4, 2025
Maintained: Hold
Price Target: $4 → $6
Current: $3.50
Upside: +71.43%
May 7, 2025
Maintained: Buy
Price Target: n/a
Current: $8.45
Upside: n/a
Mar 13, 2025
Maintained: Buy
Price Target: $37 → $41
Current: $22.71
Upside: n/a
Dec 5, 2024
Maintained: Buy
Price Target: $4 → $6
Current: $1.59
Upside: n/a
Nov 11, 2024
Maintained: Buy
Price Target: $38 → $33
Current: $13.58
Upside: n/a
Nov 15, 2022
Maintained: Buy
Price Target: $4
Current: $3.60
Upside: n/a
Apr 10, 2022
Maintained: Buy
Price Target: $8 → $3
Current: $0.0001
Upside: n/a
Jun 3, 2021
Maintained: Buy
Price Target: $30 → $31
Current: $19.59
Upside: n/a